Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
NCT07270783Phase 1Active, not recruiting
- Sponsor
- InventisBio
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of D-2570 (3 cohorts), sponsored by InventisBio. Primary endpoints: Incidence of adverse events at 48 days and Pharmacokinetic endpoint at 20 days. Started Dec 2025; status: active, not recruiting.
02
Drugs
D-2570
Beyond the preview
Go deeper on NCT07270783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270783.